Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Melanoma brain metastases and vemurafenib: need for further investigation.

Mayo Clinic proceedings - 1 Oct 2012

Rochet Nicole M, Dronca Roxana S, Kottschade Lisa A, Chavan Rahul N, Gorman Brian, Gilbertson Julie R, Markovic Svetomir N

Abstract excerpt

Brain metastases are a major cause of morbidity and mortality in patients with advanced melanoma. With the development of targeted agents for the treatment of metastatic melanoma, a great deal of interest has focused on whether selective BRAF inhibitors may play a role in the treatment of brain metastases in lieu of or in addition to surgery and/or radiation therapy. However, relatively little is known about the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Fatal Outcome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Melanoma

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Share to Sulfonamides

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 23036672
DOI: 10.1016/j.mayocp.2012.07.006
PMCID: PMC3538399

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Melanoma brain metastases and vemurafenib: need for further investigation.PMID 23036672Read ↗

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.Semantic proximity Read ↗

Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.Semantic proximity Read ↗

Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases.Semantic proximity Read ↗

A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.Semantic proximity Read ↗

Targeting brain metastases in patients with melanoma.Semantic proximity Read ↗

Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.Semantic proximity Read ↗

Vemurafenib and radiation therapy in melanoma brain metastases.Semantic proximity Read ↗

Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.Semantic proximity Read ↗

BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.Semantic proximity Read ↗

Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapies.Semantic proximity Read ↗

BRAF-MEK inhibition in melanoma brain metastases: a new hope.Semantic proximity Read ↗

Melanoma brain metastasis: overview of current management and emerging targeted therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.